iLet Dosing Decision Software
Beta Bionics, Inc. · Decision date Sep 11, 2026
What did the FDA decide?
On September 11, 2026, the FDA recorded a substantially equivalent (SESE) decision for K262763, the iLet Dosing Decision Software from Beta Bionics, Inc. of Irvine, California. This is a 510(k) clearance, not a premarket approval. The submission, dated August 3, 2026 and received August 4, 2026, covers a modification of the cleared iLet Dosing Decision Software (K232224) under 21 CFR 862.1356, Class II, product code QJI, in the Clinical Chemistry specialty.
The recorded change is a new user interface, the iLet Mobile App, replacing the iLet Bionic Pancreas interface, plus an individual meal reset feature that returns the learning for Breakfast, Lunch or Dinner to the weight-based default. The summary describes the device as identical to the predicate in intended use, communication with an ACE pump, required user inputs, maximum basal rate, glucose targets, and bolus limits. The summary document ends at a heading for non-clinical testing and special controls; the testing detail and any clinical performance data are not present in the public information.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Clinical Chemistry
- Decision date
- Sep 11, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262763
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Beta Bionics, Inc.
- Product code
- QJI
- Decision code
- SESE
- Decision date
- Sep 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Interoperable Automated Glycemic Controller.
- Applicant
- Beta Bionics, Inc.
- Product code
- QJI
- FDA device class
- 2
FDA decision timeline
K262763 received
Application receipt date recorded by FDA.
K262763 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code QJI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
twiist Loop AlgorithmK262576 | Deka Research and Development Corp. | 510(k) clearance | Oct 15, 2026 | FDA |
iOS CamAPS FXK261896 | CamDiab | 510(k) clearance | Sep 16, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Beta Bionics, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Irvine, CA
Sources and methodology
- Original FDA record: K262763
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
